

[An article in Time Magazine online this weekend](#) highlighted rare diseases (those which, like NF, affect fewer than 100,000 Americans). The brief article highlights the growing interest of industry in this arena, as biotech and pharma begin to look for unexplored markets and are seeing the potential commercial value of working in rare diseases.